UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: October 9, 2020
| MEREO BIOPHARMA GROUP PLC | ||
| By: | /s/ Charles Sermon | |
| Name: Charles Sermon | ||
| Title: General Counsel | ||
Exhibit 99.1
Mereo BioPharma Group plc
Director and PDMR Dealings
London and Redwood City, Calif., October 9, 2020 – Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 7 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 12,711 American Depositary Shares (ADSs) at a price of USD 2.36 per ADS, Brian Schwartz, Non-Executive Director of Mereo, purchased 20,000 ADSs at a price of USD 2.35 per ADS and John Richard, Head of Corporate Development of Mereo, purchased 6,500 ADSs at a price of USD 2.36 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
| 1 | Details of the person discharging managerial responsibilities | |||||||||
| a) | Name | Denise Scots-Knight | ||||||||
| 2 | Reason for the notification | |||||||||
| a) | Position/status | Chief Executive Officer | ||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mereo BioPharma Group plc | ||||||||
| b) | LEI | 213800U8JQHIJOS5AS09 | ||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) | ||||||||
| b) | Nature of the transaction | PURCHASE | ||||||||
| c) | Price(s) and volume(s) | |||||||||
| Price(s) | Volume(s) | |||||||||
| USD 2.36 | 12,711 | |||||||||
| d) | Aggregated information: volume, Price | 30043.72 | ||||||||
| e) | Date of the transaction | 2020-10-07 | ||||||||
| f) | Place of the transaction | XNMS | ||||||||
| 1 | Details of the person discharging managerial responsibilities | |||||||||
| a) | Name | Brian Schwartz | ||||||||
| 2 | Reason for the notification | |||||||||
| a) | Position/status | Non-Executive Director | ||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mereo BioPharma Group plc | ||||||||
| b) | LEI | 213800U8JQHIJOS5AS09 | ||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) | ||||||||
| b) | Nature of the transaction | PURCHASE | ||||||||
| c) | Price(s) and volume(s) | |||||||||
| Price(s) | Volume(s) | |||||||||
| USD 2.35 | 20,000 | |||||||||
| d) | Aggregated information: volume, Price | 47068.00 | ||||||||
| e) | Date of the transaction | 2020-10-07 | ||||||||
| f) | Place of the transaction | XNMS | ||||||||
| 1 | Details of the person discharging managerial responsibilities | |||||||||
| a) | Name | John Richard | ||||||||
| 2 | Reason for the notification | |||||||||
| a) | Position/status | Head of Corporate Development | ||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mereo BioPharma Group plc | ||||||||
| b) | LEI | 213800U8JQHIJOS5AS09 | ||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) | ||||||||
| b) | Nature of the transaction | PURCHASE | ||||||||
| c) | Price(s) and volume(s) | |||||||||
| Price(s) | Volume(s) | |||||||||
| USD 2.36 | 6,500 | |||||||||
| d) | Aggregated information: volume, Price | 15330.06 | ||||||||
| e) | Date of the transaction | 2020-10-07 | ||||||||
| f) | Place of the transaction | XNMS | ||||||||